Factor II- and factor Xa-inhibitors for prevention and treatment of thromboses / Faktor II- und Faktor Xa-Inhibitoren in der Prävention und Therapie von Thrombosen

2009 ◽  
Vol 33 (2) ◽  
pp. 121-127
Author(s):  
Matthias Orth
Keyword(s):  
Factor Xa ◽  
Factor Xa Inhibitors ◽  
Factor Ii ◽  
Prevention And Treatment ◽  
Faktor Xa ◽  
Prävention Und Therapie

scholarly journals Role of Factor Xa Inhibitors in Cancer-Associated Thrombosis: Any New Data?

2011 ◽  
Vol 2011 ◽  
pp. 1-12 ◽  
Author(s):  
Ali Zalpour ◽  
Michael H. Kroll ◽  
Vahid Afshar-Kharghan ◽  
Syed Wamique Yusuf ◽  
Carmen Escalante
Keyword(s):  
Clinical Trials ◽  
Cancer Patients ◽  
Anticoagulation Therapy ◽  
Factor Xa ◽  
Factor Xa Inhibitors ◽  
The Us ◽  
Prevention And Treatment ◽  
Cancer Associated Thrombosis ◽  
Current Guidelines

The association between cancer and venous thromboembolism (VTE) has been well documented in the literature. Prevention and treatment of VTE in cancer patients is imperative. Typically, the mainstay regimen for VTE prevention and treatment has been anticoagulation therapy, unless contraindicated. This therapy consists of unfractionated heparin (UFH), low-molecular-weight heparin (LMWH), factor Xa inhibitor, or vitamin K antagonist (VKA). Current guidelines recommend LMWH over VKA for the treatment of VTE in cancer patients. Factor-specific anticoagulants have been proven safe and effective, and recently factor Xa inhibitors have emerged as a treatment alternative to heparins and VKA. Currently, three factor Xa inhibitors have been identified: fondaparinux (the only one approved so far by the US Food and Drug Administration), idraparinux (in clinical trials), and idrabiotaparinux (in clinical trials). This paper will examine the role of these agents, focusing on fondaparinux, for the prevention and treatment of VTE in cancer patients.

Anticoagulation Therapy. Heparins, Factor II and Factor Xa Inhibitors

2013 ◽  
pp. 59-122
Author(s):  
Ana Muñiz-Lozano ◽  
Fabiana Rollini ◽  
Francesco Franchi ◽  
Dominick J. Angiolillo
Keyword(s):  
Anticoagulation Therapy ◽  
Factor Xa ◽  
Factor Xa Inhibitors ◽  
Factor Ii

Comparison of the Anticoagulant and Antithrombotic Effects of Synthetic Thrombin and Factor Xa Inhibitors

1990 ◽  
Vol 63 (02) ◽  
pp. 220-223 ◽  
Author(s):  
J Hauptmann ◽  
B Kaiser ◽  
G Nowak ◽  
J Stürzebecher ◽  
F Markwardt
Keyword(s):  
Factor Xa ◽  
Thrombin Inhibitors ◽  
Factor Xa Inhibitors ◽  
Venous Stasis ◽  
Clotting Time ◽  
Thrombosis Model ◽  
Activity Factor ◽  
Antithrombotic Effects

SummaryThe anticoagulant effect of selected synthetic inhibitors of thrombin and factor Xa was studied in vitro in commonly used clotting assays. The concentrations of the compounds doubling the clotting time in the various assays were mainly dependent on their thrombin inhibitory activity. Factor Xa inhibitors were somewhat more effective in prolonging the prothrombin time compared to the activated partial thromboplastin time, whereas the opposite was true of thrombin inhibitors.In vivo, in a venous stasis thrombosis model and a thromboplastin-induced microthrombosis model in rats the thrombin inhibitors were effective antithrombotically whereas factor Xa inhibitors of numerically similar IQ value for the respective enzyme were not effective at equimolar dosageThe results are discussed in the light of the different prelequisiles and conditions for inhibition of thrombin and factor Xa in the course of blood clotting.

Spectrophotometric Assays of Prothrombin in Plasma of Patients Using Oral Anticoagulants

1979 ◽  
Vol 42 (04) ◽  
pp. 1296-1305 ◽  
Author(s):  
R M Bertina ◽  
W van der Marel-van Nieuwkoop ◽  
E A Loeliger
Keyword(s):  
Prothrombin Time ◽  
Vitamin K ◽  
Oral Anticoagulation ◽  
Vitamin K Antagonists ◽  
Oral Anticoagulants ◽  
Factor Xa ◽  
Factor V ◽  
Anticoagulant Treatment ◽  
Factor Ii ◽  
K Deficiency

SummaryTwo spectrophotometric assays for prothrombin have been developed and compared with a one stage coagulant and an immunological assay. One of these assays (called the XAPC assay) uses a combination of factor Xa, phospholipid, Ca2+ and factor V as activator of prothrombin, and measures only normal prothrombin. The second (the ECAR assay) uses Echis carinatus venom as activator. This assay measures both normal prothrombin and PIVKA II (protein induced by vitamin K antagonists/absence). Combination of the results obtained by the XAPC and ECAR assays provides rapid and reliable information on the degree of “subcarboxylation” of prothrombin (oral anticoagulation, vitamin K deficiency).For patients on long term anticoagulant treatment the prothrombin time (Thrombotest) shows better correlation with the ratio prothrombin/prothrombin plus PIVKA II (XAPC/ ECAR) than with the factor II concentration. For patients starting the anticoagulant treatment there is no correlation between the Thrombotest time and the XAPC/ECAR ratio.It seems doubtful that (a) spectrophotometric factor II assay(s) will be as useful as the prothrombin time in the control of oral anticoagulation.

Analyses of Activity for Factor Xa Inhibitors Based on Monte Carlo Simulations

2003 ◽  
Vol 46 (26) ◽  
pp. 5691-5699 ◽  
Author(s):  
Dennis Ostrovsky ◽  
Marina Udier-Blagović ◽  
William L. Jorgensen
Keyword(s):  
Monte Carlo ◽  
Monte Carlo Simulations ◽  
Factor Xa ◽  
Factor Xa Inhibitors
Sign in / Sign up

Export Citation Format

Share Document